• Tissue-Dependent Expression and Translation of Circular RNAs with Recombinant AAV Vectors In Vivo. Meganck RM, Borchardt EK, Castellanos Rivera RM, Scalabrino ML, Wilusz JE, Marzluff WF, Asokan A. Mol Ther Nucleic Acids. 2018 Dec 7;13:89-98.

  • Aquaporin-4-dependent glymphatic solute transport in the rodent brain. Mestre H, Hablitz LM, Xavier AL, Feng W, Zou W, Pu T, Monai H, Murlidharan G, Castellanos Rivera RM, Simon MJ, Pike MM, Plá V, Du T, Kress BT, Wang X, Plog BA, Thrane AS, Lundgaard I, Abe Y, Yasui M, Thomas JH, Xiao M, Hirase H, Asokan A, Iliff JJ, Nedergaard M. Elife. 2018 Dec 18;7. pii: e40070.

  • Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion. Castle MJ, Cheng Y, Asokan A, Tuszynski MH. Sci Adv. 2018 Nov 14;4(11):eaau9859.

  • Mapping and Engineering Functional Domains of the Assembly Activating Protein of Adeno-Associated Viruses. Tse LV, Moller-Tank S, Meganck RM, Asokan A. J Virol. 2018 Apr 25. pii: JVI.00393-18. [link]

  • Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Albright BH, Storey CM, Murlidharan G, Castellanos Rivera RM, Berry GE, Madigan VJ, Asokan A. Mol Ther. 2018 Feb 7;26(2):510-523. [link]

  • An Adeno-Associated Virus-Based Toolkit for Preferential Targeting and Manipulating Quiescent Neural Stem Cells in the Adult Hippocampus. Crowther AJ, Lim SA, Asrican B, Albright BH, Wooten J, Yeh CY, Bao H, Cerri DH, Hu J, Ian Shih YY, Asokan A, Song J. Stem Cell Reports. 2018 Mar 13;10(3):1146-1159. [link]


  • Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques. Burwitz BJ, Wettengel JM, Mück-Häusl MA, Ringelhan M, Ko C, Festag MM, Hammond KB, Northrup M, Bimber BN, Jacob T, Reed JS, Norris R, Park B, Moller-Tank S, Esser K, Greene JM, Wu HL, Abdulhaqq S, Webb G, Sutton WF, Klug A, Swanson T, Legasse AW, Vu TQ, Asokan A, Haigwood NL, Protzer U, Sacha JB. Nat Commun. 2017 Dec 15;8(1):2146. [link]

  • Primary Cilia Signaling Shapes the Development of Interneuronal Connectivity. Guo J, Otis JM, Higginbotham H, Monckton C, Cheng J, Asokan A, Mykytyn K, Caspary T, Stuber GD, Anton ES. Dev Cell. 2017 Aug 7;42(3):286-300. [link]

  • Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Tse LV, Klinc KA, Madigan VJ, Castellanos Rivera RM, Wells LF, Havlik LP, Smith JK, Agbandje-McKenna M, Asokan A. Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4812-E4821. [link]

  • Inducing circular RNA formation using the CRISPR endoribonuclease Csy4. Borchardt EK, Meganck RM, Vincent HA, Ball CB, Ramos SBV, Moorman NJ, Marzluff WF, Asokan A. RNA. 2017 May;23(5):619-627. [link]

  • Probing the Link among Genomic Cargo, Contact Mechanics, and Nanoindentation in Recombinant Adeno-Associated Virus 2. Zeng C, Moller-Tank S, Asokan A, Dragnea B. J Phys Chem B. 2017 Mar 2;121(8):1843-1853. [link]


  • Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain. Murlidharan G, Crowther A, Reardon RA, Song J, Asokan A. JCI Insight. 2016 Sep 8;1(14):e88034. [link]

  • Cellular transduction mechanisms of adeno-associated viral vectors. Berry GE, Asokan A. Curr Opin Virol. 2016 Aug 18;21:54-60. [link]

  • CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector. Murlidharan G, Sakamoto K, Rao L, Corriher T, Wang D, Gao G, Sullivan P, Asokan A. Mol Ther Nucleic Acids. 2016 Jul 19;5(7):e338. [link]

  • Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies. Tseng YS, Vliet KV, Rao L, McKenna R, Byrne BJ, Asokan A, Agbandje-McKenna M. J Virol Methods. 2016 Jul 14;236:105-110. [link]

  • Resolving Adeno-Associated Viral Particle Diversity With Charge Detection Mass Spectrometry. Pierson EE, Keifer DZ, Asokan A, Jarrold MF. Anal Chem. 2016 Jul 5;88(13):6718-25. [link]

  • Engineering AAV receptor footprints for gene therapy. Madigan VJ, Asokan A. Curr Opin Virol. 2016 Jun;18:89-96. [link]

  • rAAV compatible minipromoters for restricted expression in the brain and the eye. de Leeuw et al., Mol Brain. 2016. [link]

  • Characterization of the AAV1 and 6 sialic acid binding site. Huang LY et al., J Virol. 2016. [link]

  • In vivo genome editing improves muscle function in a mouse model of Duchenne Muscular Dystrophy. Nelson et al., Science. 2016. [link]

  • Chemical modulation of endocytic sorting augments AAV transduction. Berry GE, Asokan A. J Biol Chem. 2016. [link]


  • Controlling mRNA stability and translation with the CRISPR endoribonuclease Csy4. Borchardt EK, Vandoros LA, Huang M, Lackey PE, Marzluff WM, Asokan A. RNA. 2015. [link]

  • An siRNA screen identifies the U2 snRNP spliceosome as a host restriction factor for recombinant adeno-associated viruses. Schreiber CA et al., PLoS Pathogens. 2015. [link]

  • Strategies to circumvent humoral immunity to adeno-associated viral vectors. Tse LV, Moller-Tank S, Asokan A. Expert Opin. Biol. Ther. 2015 [link]

  • Development of patient specific AAV vectors after neutralizing antibody selection for enhanced muscle gene transfer. Li C et al., Mol Ther. 2015. [link]

  • Optical control of CRISPR/Cas9 gene editing. Hemphill J, Borchardt EK et al. J Am Chem Soc. 2015 [link]

  • Unique glycan signatures regulate AAV tropism in the developing brain. Murlidharan G, Corriher T, Ghashghaei HT, Asokan A. J Virol. 2015. [link]

  • Functional analysis of the putative integrin recognition motif on adeno-associated virus 9. Shen et al., J Biol Chem. 2015. [link]


  • Biology of AAV vectors in the central nervous system. Murlidharan G, Samulski RJ, Asokan A. Front Mol Neurosci. 2014. [link]

  • Gene Therapy: Charting a Future Course - Summary a NIH Workshop. O'Reilly M et al., Hum Gene Ther. 2014. 35: 488-97. [link]

  • Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and pharmacology of analgesic drugs. Pleitcha J et al. Mol Pain. 2014. 10:54. [link]

  • Cardiac I-1c overexpression with reengineered AAV vector improves cardiac function in swine ischemic heart failure. Ishikawa K et al., Mol Ther. 2014. Epub. [link]


  • An emerging AAV vector pipeline for cardiac gene therapy. Asokan A, Samulski RJ. 2013. 24(11): 906-913. [link]

  • Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4.  Shen S, Troupes AN, Pulicherla N, Asokan A. J Virol. 2013. 87(24): 13206-13. [link]

  • Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. Shen S, Horowitz ED, Troupes AN, Brown SM, Pulicherla N, Samulski RJ, Agbandje-McKenna M, Asokan A. J Biol Chem. 2013. 288: 28814-23. [link]

  • Biophysical and ultrastructural characterization of adeno-associated viral capsid uncoating and genome release. Horowitz ED, Rahman KS, Bower BD, Dismuke DJ, Galvo MC, Griffith JD, Harvery SC, Asokan A. J Virol. 2012. 87: 2994-3002. [link]


  • Glycan binding avidity determines the systemic fate of adeno-associated virus 9. Shen S, Bryant K, Sun J, Brown S, Troupes A, Pulicherla N, Asokan A. J Virol. 2012. 86: 10408-17. [link]

  • Single amino acid modification of AAV capsids changes transduction and humoral immune profiles. Li C, DiPrimio N, Bowles DE, Hirsch ML, Monahan PE, Asokan, Rabinowitz JE, Agbandje-McKenna M, Samulski RJ. J Virol. 2012. 86: 7752-9. [link]

  • Human Galectin 3 binding protein interacts with recombinant AAV serotype 6. Denard J, Beley C, Kotin R, Lai-Kuen R, Blot S, Leh H, Asokan A, Samulski RJ, Moullier P, Voit T, Garcia L, Svinartchouk F. J Virol. 2012. 86: 6620-31. [link]

  • Tyrosine Cross-Linking Reveals Interfacial Dynamics in Adeno-Associated Viral Capsids during Infection. Horowitz ED, Finn MG, Asokan A. ACS Chem Biol. 2012. 7: 1059-66. [link]

  • Intra- and inter-subunit disulfide bond formation is nonessential in adeno-associated viral capsids. Pulicherla N, Kota P, Dokholyan NV, Asokan A. PLoS One. 2012;7(2):e32163. [link]

  • Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Li C, Narkbunnam N, Samulski, RJ, Asokan A, Monahan PE et al. Gene Ther. 2012. 19: 288-94. [link]

  • Bocavirus episome in infected human tissue contains non-identical termini. Kapoor A, Hornig M, Asokan A, Williams B, Henriquez JA, Lipkin WI. PLoS One. 2012. 6: e21362. [link]

  • The AAV vector toolkit: poised at the clinical crossroads. Asokan A, Schaffer DV, Samulski RJ. Mol Ther. 2012 Apr;20(4):699-708. [link]


  • Peptide Affinity Reagents for AAV Capsid Recognition and Purification. Nagesh Pulicherla and Aravind Asokan. Gene Ther. 2011. 18: 1020-4. [link]

  • Glycated AAV Vectors: Chemical Redirection of Viral Tissue Tropism. Horowitz ED, Weinberg MS, Asokan A. Bioconjug Chem. 2011. 22: 529-532. [link]

  • Engineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene Transfer.Pulicherla N, Shen S, Yadav S, Debbink K, Govindasamy L, Agbandje-McKenna M, Asokan A. Mol Ther. 2011. 19: 1070-8. [link]

  • Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. Shen Shen, Kelli D. Byrant, Sarah M. Brown, Scott H. Randell  Aravind Asokan. J Biol Chem. 2011. 286: 13532-40. [link]

  • Systemic gene transfer to skeletal muscle using reengineered AAV vectors. 2011. 709: 141-151. [link]


  • Reengineered AAV vectors: old dog, new tricks. Aravind Asokan.  Discov Med. 2010. 9: 399-403. [link]

  • Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, Sinnott R, Yadav S, DiPrimio N, Nam HJ, Agbandje-McKenna M, McPhee S, Wolff J, Samulski RJ. Nat Biotechnol. 2010. 28: 79-82. [link]

Prior to 2010, click here